Onychomycosis

Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes
Published:March 26, 2016DOI:https://doi.org/10.1016/j.cpm.2016.02.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Podiatric Medicine and Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ghannoum M.A.
        • Hajjeh R.A.
        • Scher R.
        • et al.
        A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns.
        J Am Acad Dermatol. 2000; 43: 641-648
        • Thomas J.
        • Jacobson G.A.
        • Narkowicz C.K.
        • et al.
        Toenail onychomycosis: an important global disease burden.
        J Clin Pharm Ther. 2010; 35: 497-519
        • Borman A.M.
        • Campbell C.K.
        • Fraser M.
        • et al.
        Analysis of the dermatophyte species isolated in the British Isles between 1980 and 2005 and review of worldwide dermatophyte trends over the last three decades.
        Med Mycol. 2007; 45: 131-141
        • Saunte D.M.
        • Svejgaard E.L.
        • Haedersdal M.
        • et al.
        Laboratory-based survey of dermatophyte infections in Denmark over a 10-year period.
        Acta Derm Venereol. 2008; 88: 614-616
        • Zaias N.
        Onychomycosis.
        Dermatol Clin. 1985; 3: 445-460
        • Westerberg D.P.
        • Yoyack M.J.
        Onychomycosis: current trends in diagnosis and treatment.
        Am Fam Physician. 2013; 88: 762-770
        • Gupta A.K.
        • Skinner A.R.
        • Baran R.
        Onychomycosis in children: an overview.
        J Drugs Dermatol. 2003; 2: 31-34
        • Hay R.J.
        • Baran R.
        Onychomycosis: a proposed revision of the clinical classification.
        J Am Acad Dermatol. 2011; 65: 1219-1227
        • Faergemann J.
        • Baran R.
        Epidemiology, clinical presentation and diagnosis of onychomycosis.
        Br J Dermatol. 2003; 149: 1-4
        • Murphy F.
        • Jiaravuthisan M.M.
        • Sasseville D.
        • et al.
        Psoriasis of the nail: anatomy, pathology, clinical presentation, and review of the literature on therapy.
        J Am Acad Dermatol. 2007; 57: 1-27
        • Rich P.
        • Elewski B.
        • Scher R.K.
        • et al.
        Diagnosis, clinical implications, and complications of onychomycosis.
        Semin Cutan Med Surg. 2013; 32: S5-S8
        • Moll J.M.
        Seronegative arthropathies in the foot.
        Baillieres Clin Rheumatol. 1987; 1: 289-314
        • Fletcher C.L.
        • Hay R.J.
        • Smeeton N.C.
        Onychomycosis: the development of a clinical diagnostic aid for toenail disease. Part I. Establishing discriminating historical and clinical features.
        Br J Dermatol. 2004; 150: 701-705
        • Weinberg J.M.
        • Koestenblatt E.K.
        • Tutrone W.D.
        • et al.
        Comparison of diagnostic methods in the evaluation of onychomycosis.
        J Am Acad Dermatol. 2003; 49: 193-197
        • Reisberger E.M.
        • Abels C.
        • Landthaler M.
        • et al.
        Histopathological diagnosis of onychomycosis by periodic acid-Schiff-stained nail clippings.
        Br J Dermatol. 2003; 148: 749-754
        • Borkowski P.
        • Williams M.
        • Holewinski J.
        • et al.
        Onychomycosis: an analysis of 50 cases and a comparison of diagnostic techniques.
        J Am Podiatr Med Assoc. 2001; 91: 351-355
        • Elewski B.E.
        Diagnostic techniques for confirming onychomycosis.
        J Am Acad Dermatol. 1996; 35: 56-60
        • Arca E.
        • Saracli M.A.
        • Akar A.
        • et al.
        Polymerase chain reaction in the diagnosis of onychomycosis.
        Eur J Dermatol. 2004; 14: 52-55
        • Pierard G.E.
        • Arrese-Estrada J.
        • Pierard-Franchimont C.
        Treatment of onychomycosis: traditional approaches.
        J Am Acad Dermatol. 1993; 29: S41-S45
        • Spreadbury C.
        • Holden D.
        • Aufaurre-Brown A.
        • et al.
        Detection of aspergillus fumigatus by polymerase chain reaction.
        J Clin Microbiol. 1993; 31: 615-621
        • Miyakawa Y.
        • Mabuchi T.
        • Kagaya K.
        • et al.
        Isolation and characterization of a species-specific DNA fragment for detection of Candida albicans by polymerase chain reaction.
        J Clin Microbiol. 1992; 30: 894-900
        • Baharaeen S.
        • Vishniac H.S.
        25S ribosomal RNA homologies of basidiomycetous yeasts: taxonomic and phylogenetic implications.
        Can J Microbiol. 1984; 30: 613-621
        • Walberg M.
        • Mørk C.
        • Sandven P.
        • et al.
        18S rDNA polymerase chain reaction and sequencing in onychomycosis diagnostics.
        Acta Derm Venereol. 2006; 86: 223-226
        • Ameen M.
        • Lear J.T.
        • Madan V.
        • et al.
        British Association of Dermatologists’ guidelines for the management of onychomycosis 2014.
        Br J Dermatol. 2014; 171: 937-958
        • Thatai P.
        • Sapra B.
        Transungual delivery: deliberations and creeds.
        Int J Cosmet Sci. 2014; 36: 398-411
        • Kobayashi Y.
        • Miyamoto M.
        • Sugibayashi K.
        • et al.
        Drug permeation through the three layers of the human nail plate.
        J Pharm Pharmacol. 1999; 51: 271-278
        • Gupta A.K.
        • Joseph W.S.
        Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.
        J Am Podiatr Med Assoc. 2000; 90: 495-501
        • Bohn M.
        • Kraemer K.
        The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
        J Am Podiatr Med Assoc. 2000; 90: 491-494
        • Hamilton J.B.
        • Terada H.
        • Mestler G.E.
        Studies of growth throughout the lifespan in Japanese: growth and size of nails and their relationship to age, sex, heredity, and other factors.
        J Gerontol. 1955; 10: 401-415
        • Elewski B.E.
        • Rich P.
        • Wiltz H.
        • et al.
        Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent for the treatment of onychomycosis: results from two randomized phase 3 studies.
        J Am Acad Dermatol. 2015; 73: 62-69
        • Elewski B.E.
        • Rich P.
        • Pollak R.
        • et al.
        Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase 3 multicenter, randomized, double-blind studies.
        J Am Acad Dermatol. 2013; 68: 600-608
        • Elewski B.E.
        • Pollak R.A.
        • Pillai R.
        • et al.
        Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
        J Drugs Dermatol. 2014; 13: 1394-1398
        • Gupta A.K.
        • Pillai R.K.
        The presence of an air gap between the nail plate and nail bed in onychomycosis patients: treatment implications for topical therapy.
        J Drugs Dermatol. 2015; 14: 859-863
        • Singh G.
        • Haneef N.S.
        • Uday A.
        Nail changes and disorders among the elderly.
        Indian J Dermatol Venereol Leprol. 2005; 71: 386-392
        • Baran R.
        • Kaoukhov A.
        Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
        J Eur Acad Dermatol Venereol. 2005; 19: 21-29
        • Lecha M.
        • Effendy I.
        • Feuilhade de Chauvin M.
        • et al.
        Treatment options—development of consensus guidelines.
        J Eur Acad Dermatol Venereol. 2005; 19: 25-33
      1. Jublia (efinaconazole topical solution, 10%) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals LLC; 2014.

        • Zeichner J.A.
        • Stein Gold L.
        • Korotzer A.
        Penetration of (14C)-Efinaconazole solution does not appear to be influenced by nail polish.
        J Clin Aesthet Dermatol. 2014; 7: 45-48
        • Vlahovic T.
        • Merchant T.
        • Chanda S.
        • et al.
        In vitro nail penetration of tavaborole topical solution, 5% through nail polish on ex vivo human fingernails.
        J Drugs Dermatol. 2015; 14: 675-678
        • Del Rosso J.Q.
        Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis.
        J Am Osteopath Assoc. 1997; 97: 339-346
        • Sigurgeirsson B.
        • Billstein S.
        • Rantanen T.
        • et al.
        L.I.ON. Study: efficacy and tolerability of continuous terbinafine compared to intermittent itraconazole in the treatment of toenail onychomycosis.
        Br J Dermatol. 1999; 141: 5-14
        • Baran R.
        • Tosti A.
        • Hartmane I.
        • et al.
        An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis.
        J Eur Acad Dermatol Venereol. 2009; 23: 773-781
        • Baran R.
        • Sigurgeirsson B.
        • de Berker D.
        • et al.
        A multicenter, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis.
        Br J Dermatol. 2007; 157: 149-157
        • Hay R.J.
        The future of onychomycosis therapy may involve a combination of approaches.
        Br J Dermatol. 2001; 145: 3-8
        • Rosen T.
        Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10%.
        Cutis. 2015; 96: 197-201
        • Rodriguez D.A.
        Efinaconazole topical solution, 10% for the treatment of mild and moderate toenail onychomycosis.
        J Clin Aesthet Dermatol. 2015; 8: 24-29
        • Markinson B.
        • Caldwell B.
        Efinaconazole topical solution, 10%: efficacy in onychomycosis patients with co-existing tinea pedis.
        J Am Podiatr Med Assoc. 2015; 105: 407-411
        • Rich P.
        Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early.
        J Drugs Dermatol. 2015; 14: 58-62
        • Potter L.P.
        • Mathias S.D.
        • Raut M.
        • et al.
        The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis.
        J Dermatolog Treat. 2007; 18: 46-52
        • Malay D.S.
        • Yi S.
        • Borowsky P.
        • et al.
        Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial.
        J Foot Ankle Surg. 2009; 48: 294-308
        • Jennings M.B.
        • Pollak R.
        • Harkless L.B.
        • et al.
        Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial.
        J Am Podiatr Med Assoc. 2006; 96: 465-473
        • Markinson B.C.
        • Vlahovic T.C.
        • Joseph W.S.
        • et al.
        Diagnosis and management of onychomycosis: perspectives from a joint podiatry-dermatology roundtable.
        J Am Podiatr Med Assoc. 2015; ([Epub ahead of print])
        • Gupta A.K.
        • Paquet M.
        • Simpson F.C.
        Therapies for the treatment of onychomycosis.
        Clin Dermatol. 2013; 31: 544-554
        • Ortiz A.E.
        • Avram M.M.
        • Wanner M.A.
        A review of lasers and light for the treatment of onychomycosis.
        Lasers Surg Med. 2014; 46: 117-124
        • Bristow I.R.
        The effectiveness of lasers in the treatment of onychomycosis: a systematic review.
        J Foot Ankle Res. 2014; 7: 34
        • Evans E.
        The rationale for combination therapy.
        Br J Dermatol. 2001; 145: 9-13
        • Olafsson J.H.
        • Sigurgeirsson B.
        • Baran R.
        Combination therapy for onychomycosis.
        Br J Dermatol. 2003; 149: 15-18
        • Avner S.
        • Nir N.
        • Henri T.
        Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
        J Dermatolog Treat. 2005; 16: 327-330
        • Rigopoulos D.
        • Katoulis A.C.
        • Ioannides D.
        A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis.
        Br J Dermatol. 2003; 149: 151-156
        • Xu Y.
        • Miao X.
        • Zhou B.
        • et al.
        Combined oral terbinafine and long-pulsed 1,064-nm Nd: YAG laser treatment is more effective for onychomycosis than either treatment alone.
        Dermatol Surg. 2014; 40: 1201-1207
        • Grover C.
        • Bansal S.
        • Nanda S.
        • et al.
        Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial.
        Br J Dermatol. 2007; 157: 364-368
        • Pandhi D.
        • Verma P.
        Nail avulsion: indications and methods (surgical nail avulsion).
        Indian J Dermatol Venereol Leprol. 2012; 78: 299-308
        • Scher R.K.
        • Baran R.
        Onychomycosis in clinical practice: factors contributing to recurrence.
        Br J Dermatol. 2003; 149: 5-9
        • Ko J.Y.
        • Lee H.E.
        • Jae H.
        • et al.
        Cure rate, duration required for complete cure and recurrence rate of onychomycosis according to clinical factors in Korean patients.
        Mycoses. 2011; 54: 384-388
        • Heikkila H.
        • Stubb S.
        Long-term results of patients with onychomycosis treated with itraconazole.
        Acta Derm Venereol. 1997; 77: 70-71
        • Piraccini B.M.
        • Sisti A.
        • Tosti A.
        Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents.
        J Am Acad Dermatol. 2010; 62: 411-414
        • Watson A.B.
        • Marley J.E.
        • Ellis D.H.
        • et al.
        Long-term follow up of patients with toenail onychomycosis after treatment with terbinafine.
        Australas J Dermatol. 1998; 39: 29-30
        • Yin Z.
        • Xu J.
        • Luo D.
        A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole.
        J Dermatolog Treat. 2012; 23: 449-452
        • Sigurgeirsson B.
        • Olafsson J.H.
        • Steinsson J.T.
        • et al.
        Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years.
        J Eur Acad Dermatol Venereol. 2010; 24: 910-915
        • Warshaw E.M.
        • St Clair K.R.
        Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%.
        J Am Acad Dermatol. 2005; 53: 717-720
        • Arroll B.
        • Oakley A.
        Preventing long term relapsing tinea unguium with topical anti-fungal cream: a case report.
        Cases J. 2009; 2: 70
        • Sigurgeirsson B.
        • Olafsson J.H.
        • Steinsson J.B.
        • et al.
        Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study.
        Arch Dermatol. 2002; 138: 353-357
        • Tabara K.
        • Szewczyk A.E.
        • Bienias W.
        • et al.
        Amorolfine vs. ciclopirox – lacquers for the treatment of onychomycosis.
        Postepy Dermatol Alergol. 2015; 32: 40-45
        • Sakamoto M.
        • Sugimoto N.
        • Kawabata H.
        • et al.
        Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vivo fungicidal activity in the human nails.
        J Drugs Dermatol. 2014; 13: 1338-1392
        • Scher R.K.
        • Tavakkol A.
        • Sigurgeirsson B.
        • et al.
        Onychomycosis: diagnosis and definition of cure.
        J Am Acad Dermatol. 2007; 56: 939-944
        • Ghannoum M.
        • Isham N.
        • Catalano V.
        A second look at efficacy criteria for onychomycosis: clinical and mycological cure.
        Br J Dermatol. 2014; 170: 182-187
        • Shemer A.
        • Sakka N.
        • Baran R.
        • et al.
        Clinical comparison and complete cure rates of terbinafine efficacy in affected onychomycotic toenails.
        J Eur Acad Dermatol Venereol. 2015; 29: 521-526
        • Bonifaz A.
        • Vazquez-Gonzalez D.
        • Hernandez M.A.
        • et al.
        Dermatophyte isolation in the socks of patients with tinea pedis and onychomycosis.
        J Dermatol. 2013; 40: 504-505
        • Feuilhade de Chauvin M.
        A study on the decontamination of insoles colonized by Trichophyton rubrum: effect of terbinafine spray powder 1% and terbinafine spray solution 1%.
        J Eur Acad Dermatol Venereol. 2012; 26: 875-878
        • Ghannoum M.A.
        • Isham N.
        • Long L.
        Optimization of an infected shoe model for the evaluation of an ultraviolet show sanitizer device.
        J Am Podiatr Med Assoc. 2012; 102: 309-313
        • Gupta A.K.
        • Brintnell W.C.
        Sanitization of contaminated footwear from onychomycosis patients using ozone gas: a novel adjunct therapy for treating onychomycosis and tinea pedis?.
        J Cutan Med Surg. 2013; 17: 243-249
        • Gupta A.K.
        • Brintnell W.
        Ozone gas effectively kills laboratory strains of Trichophyton rubrum and Trichphyton mentagrophytes using an in vitro test system.
        J Dermatolog Treat. 2014; 25: 251-255
        • Fisher E.
        How long do dermatophytes survive in the water of indoor pools?.
        Dermatologica. 1982; 165: 352-354
        • Hammer T.R.
        • Mucha H.
        • Hoefer D.
        Infection risk by dermatophytes during storage and after domestic laundry and their temperature-dependent inactivation.
        Mycopathologia. 2011; 171: 43-49